WallStreetZenWallStreetZen

NASDAQ: CRBP
Corbus Pharmaceuticals Holdings Inc Stock Forecast, Predictions & Price Target

Analyst price target for CRBP

Based on 2 analysts offering 12 month price targets for Corbus Pharmaceuticals Holdings Inc.
Min Forecast
$46.00+15%
Avg Forecast
$52.00+30%
Max Forecast
$58.00+45%

Should I buy or sell CRBP stock?

Based on 2 analysts offering ratings for Corbus Pharmaceuticals Holdings Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CRBP stock forecasts and price targets.

CRBP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-13
lockedlocked$00.00+00.00%2024-03-06

1 of 1

Forecast return on equity

Is CRBP forecast to generate an efficient return?

Forecast return on assets

Is CRBP forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CRBP revenue forecast

What is CRBP's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$84.5M
Avg 2 year Forecast
$244.0M
Avg 3 year Forecast
$482.9M

CRBP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CRBP$40.00$52.00+30.00%Strong Buy
MNMD$10.25$44.33+332.52%Strong Buy
PEPG$12.71$20.00+57.36%Buy
ATAI$2.47$10.50+325.10%Strong Buy
TBPH$8.93N/AN/A

Corbus Pharmaceuticals Holdings Stock Forecast FAQ

Is Corbus Pharmaceuticals Holdings Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: CRBP) stock is to Strong Buy CRBP stock.

Out of 2 analysts, 1 (50%) are recommending CRBP as a Strong Buy, 1 (50%) are recommending CRBP as a Buy, 0 (0%) are recommending CRBP as a Hold, 0 (0%) are recommending CRBP as a Sell, and 0 (0%) are recommending CRBP as a Strong Sell.

If you're new to stock investing, here's how to buy Corbus Pharmaceuticals Holdings stock.

What is CRBP's revenue growth forecast for 2028-2030?

(NASDAQ: CRBP) Corbus Pharmaceuticals Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 39.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.55%.

Corbus Pharmaceuticals Holdings's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CRBP's revenue for 2028 to be $886,457,764, with the lowest CRBP revenue forecast at $886,457,764, and the highest CRBP revenue forecast at $886,457,764. On average, 1 Wall Street analysts forecast CRBP's revenue for 2029 to be $2,560,528,214, with the lowest CRBP revenue forecast at $2,560,528,214, and the highest CRBP revenue forecast at $2,560,528,214.

In 2030, CRBP is forecast to generate $5,066,911,991 in revenue, with the lowest revenue forecast at $5,066,911,991 and the highest revenue forecast at $5,066,911,991.

What is CRBP's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CRBP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CRBP's Price Target?

According to 2 Wall Street analysts that have issued a 1 year CRBP price target, the average CRBP price target is $52.00, with the highest CRBP stock price forecast at $58.00 and the lowest CRBP stock price forecast at $46.00.

On average, Wall Street analysts predict that Corbus Pharmaceuticals Holdings's share price could reach $52.00 by Mar 13, 2025. The average Corbus Pharmaceuticals Holdings stock price prediction forecasts a potential upside of 30% from the current CRBP share price of $40.00.

What is CRBP's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CRBP) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.